Clinical Comprehensive Evaluation of Chinese Patent Medicines in Treatment of Stable Angina Pectoris with Qi Stagnation and Blood Stasis
10.13422/j.cnki.syfjx.20240819
- VernacularTitle:中成药治疗气滞血瘀型稳定型心绞痛的临床综合评价
- Author:
Wenjuan HUANG
1
;
Bing JIANG
1
;
Shengjun ZHAO
1
Author Information
1. The Affiliated Hospital of Traditional Chinese Medicine， Xinjiang Medical University， Urumqi 830000， China
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
comprehensive clinical evaluation of drugs;
angina pectoris due to coronary heart disease;
Qi stagnation and blood stasis;
drug selection
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(19):163-169
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTen Chinese patent medicines for stable angina pectoris with qi stagnation and blood stasis were comprehensively evaluated， with the aim of providing reference for optimizing the drug list of medical institutions and promoting rational drug utilization. MethodAccording to the Expert Consensus on the Selection of Chinese Patent Medicines in Medical Institutions 2022， an evaluation framework of "6+1" dimensions was established for comprehensive evaluation of the drugs based on the indicators in three levels. ResultThe evaluation results showed that Compound Danshen dripping pills， Shexiang Baoxin pills， Di'ao Xinxuekang capsules， and Xuefu Zhuyu capsules were strongly recommended for stable angina pectoris with Qi stagnation and blood stasis， with the scores of 78.5， 76， 72， and 70.8， respectively. Suxiao Jiuxin pills， Xinkeshu Tablets， Guanxin Danshen Dripping pills， and Yindan Xinnaotong soft capsules were weakly recommended， with the scores of 68.5， 65.5， 60.5， and 60.5 respectively. Lemai pills and Yangxin Dawayimixike migao were not recommended for the time being due to their low scores （50.5 and 48.8， respectively）. There is a lack of research on special populations， pharmacokinetic parameters， post-marketing re-evaluation， and economics of the medicines. ConclusionWith the updating of Chinese patent medicines， real-world research data are needed to enhance the evidence-based support. This evaluation can only reflect the comprehensive situation at a certain stage， and dynamic evaluation remains to be carried out to provide support for decision makers.
